Skip to main content

Table 2 Therapeutic management of COPD prior to initiating fluticasone/salmeterol

From: Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study

  GPs N patients (n = 352) Pulmonologists N patients (n = 358)
General care, N (%) 1     
  Consultation with GP 320 (91.4%) 350 251 (73.6%) 341
  Consultation with specialist 173 (49.6%) 349 215 (60.6%) 355
  Emergency visits 31 (8.9%) 348 53 (14.9%) 356
  Hospitalizations 38 (10.9%) 350 71 (19.8%) 358
  Oral corticosteroids 220 (63.0%) 349 120 (33.7%) 356
  Antibiotics 289 (83.5%) 346 194 (54.6%) 355
Vaccination, N (%)     
  Flu1 264 (75.4%) 350 214 (60.1%) 355
  Pneumococcus (within 5 years) 168 (48.1%) 349 106 (30.1%) 352
Prior medication, N (%)   2682   2392
  Short-acting bronchodilator 37 (13.8%)   26 (10.9%)  
  Long-acting ± short-acting bronchodilator 57 (21.3%)   88 (36.9%)  
  ICS + long-acting bronchodilator 87 (32.5%)   92 (38.5%)  
  ICS ± short-acting bronchodilator 57 (21.3%)   23 (9.6%)  
  Other ICS combination 15 (5.6%)   6 (2.5%)  
  Other 15 (5.6%)   4 (1.6%)  
Concomitant medication, N (%) 3   1674   2584
  Long-acting anticholinergic ± short-acting bronchodilator 53 (31.7%)   173 (67.1%)  
  Short-acting bronchodilator 81 (48.5%)   71 (27.5%)  
  Long-acting β-2 adrenergic agonist 18 (10.8%)   11 (4.3%)  
  Other ICS 15 (9.0%)   3 (1.2%)  
  1. 1During the 12 months prior to inclusion.
  2. 2Missing data for 84 GP and 119 pulmonologist patients.
  3. 3At the time of FSC initiation.
  4. 4Missing data for 185 GP and 100 pulmonologist patients.